Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "regulated-markets"

146 News Found

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies
interviews | February 15, 2022

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post

Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore
News | May 15, 2026

Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore

The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives

Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority
Drug Approval | May 15, 2026

Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority

The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026

Senores Pharma doubles profit as sales surge 62%
News | May 15, 2026

Senores Pharma doubles profit as sales surge 62%

Global specialty pipeline accelerates growth

Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million
News | May 11, 2026

Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million

Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint

OneSource powers second generic semaglutide nod in Canada
Drug Approval | May 05, 2026

OneSource powers second generic semaglutide nod in Canada

Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs

OneSource Specialty Pharma's partners get Health Canada approval for generic Semaglutide injection
News | May 04, 2026

OneSource Specialty Pharma's partners get Health Canada approval for generic Semaglutide injection

Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing

Dr Reddy’s becomes first to secure Health Canada nod for generic Semaglutide injection
Drug Approval | May 01, 2026

Dr Reddy’s becomes first to secure Health Canada nod for generic Semaglutide injection

Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada

Gujarat Themis Biosyn to acquire anti-TB and anti-infective brands from Sanofi for EUR 158 Million
News | April 24, 2026

Gujarat Themis Biosyn to acquire anti-TB and anti-infective brands from Sanofi for EUR 158 Million

Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence

Supriya Lifescience receives USFDA EIR with VAI classification for Maharashtra API facility
News | April 22, 2026

Supriya Lifescience receives USFDA EIR with VAI classification for Maharashtra API facility

Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States

Latest Stories

Lupin receives USFDA nod for Famotidine injection

Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority

Alembic Pharma receives USFDA tentative approval for Darolutamide tablets

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
Dushyant Sapre Founder and CEO, SwishX
Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital
Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital
Duraisamy Rajan Palani Founder and CEO, Archimedis Digital
Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi
Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi
Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

Packaging